Groowe Groowe / Newsroom / TEVA
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

TEVA News

Teva Pharmaceutical Industries Limited American Depositary Shares

Using Antibiotics Wisely. Making Them Responsibly.

accessnewswire.com
TEVA

Chronic Refractory Cough Market is Expected to Boom by 2034 Driven by Advancements in Treatment Options | DelveInsight

globenewswire.com
GSK TREVI MRK AZN SNY TEVA JNJ PFE BMY LLY VRTX AMGN ABBV GILD BIIB CSL

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

globenewswire.com
TEVA AMGN

Medincell Awarded New Grant to Fight Malaria

businesswire.com
TEVA

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December

globenewswire.com
TEVA

Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer

globenewswire.com
NSRX PRO BCLI TEVA

Immunoassay Market Research, Strategies, Trends and Forecasts Report 2025 with Executive Guides and Impact of Artificial Intelligence - ResearchAndMarkets.com

businesswire.com
ALGN AMZN BDX BIO BMY CDNS CERN CHKP CLVS CODX CRSP CYTK DELL DGX DHR DIS DTC DXCM ENZ EXAS FSLR GILD GOOG IDXX ILMN INCY INTC ISRG JNJ LULU LUMX MDLZ MRNA MSFT MYL NBIX NCLH NFLX NVS NVTA ORCL ORGO OSIP OTIS PANW PFE PG PGR PPC PRGO QCOM QGEN QORV QUID REGN ROCH ROST SGEN SIRI SNPS SPLK SRPT SWKS SYK TCOM TEAM TEVA TGT TMO TSLA TXN ULTA UNH VRTX WBA WDC WEC WFC XRAY XTRA ZBRA

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma’s Biggest Challenges

globenewswire.com
TEVA

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

globenewswire.com
TEVA

Teva's Innovative Portfolio Drives 11th Consecutive Quarter of Growth in Q3 2025; Increases 2025 Outlook for Austedo® and Non-GAAP EPS

globenewswire.com
TEVA